News

ImmunoCellular (IMUC) has signed an agreement with Formatech for the manufacture of IMUC’s cancer stem cell vaccine, ICT-121, for an upcoming clinical trial. ICT-121 is a product candidate

Neuralstem has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, to prepare for a human clinical trial (using Neuralstem’s human spinal

Spherix has announced positive preliminary results from phase-II clinical trial of Naturlose (D-tagatose), in the treatment and management of Type 2 diabetes. The phase-II trial was single-blind, prospective,

Glenmark’s Melogliptin has recently completed 12 weeks phase-IIb clinical trial in 494 patients with type 2 diabetes mellitus, and is now ready to initiate phase III trials. In

GlaxoSmithKline (GSK) has received a complete response letter from FDA, related to the application for casopitant (Rezonic). The company is reviewing it and will slot in with the

PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced the launch of Nucynta (tapentadol) CII immediate release tablets. Nucynta works by binding with mu-opioid receptors and inhibiting norepinephrine re-uptake.

Javelin Pharmaceuticals (Javelin) has completed open-label, multi-dose, multi-day, observational safety study of Dyloject in the US, and has announced that it has successfully met its objective. The company

PharmaSwiss, Israeli licensee of BioSante Pharmaceuticals, has submitted a new drug application (NDA) for Elestrin in Israel. The Elestrin filing is based on BioSante’ FDA approved NDA for

Laboratory Corporation of America and Monogram Biosciences have entered into an agreement and plan of merger. As per the agreement, LabCorp will acquire all of the outstanding shares